Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: Implications for current clinical trials

Circulation

Volumn 112, Issue 9 SUPPL., 2005, Pages

  Hou, Dongming ^a,b   Youssef, Eyas Al Shaykh ^a,b   Brinton, Todd J ^d   Zhang, Ping ^a   Rogers, Pamela ^a   Price, Erik T ^d   Yeung, Alan C ^d   Johnstone, Brian H ^a,b   Yock, Paul G ^d   March, Keith L ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catheters; Cells; Ischemia; Myocardial infarction

Indexed keywords

8 QUINOLINOL INDIUM IN 111;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FATE; CELL LABELING; CELL TRANSFER; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY LIGATION; CORONARY VEIN; FEMALE; HEART INJURY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; INTERSTITIAL RETROGRADE CORONARY VENOUS DELIVERY; INTRACORONARY CELL DELIVERY; INTRAMYOCARDIAL CELL DELIVERY; ISOTOPE LABELING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LUNG; LUNG CIRCULATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCINTILLATION COUNTING; STEM CELL TRANSPLANTATION; SWINE; TISSUE DISTRIBUTION;

ANIMALS; CELL LINEAGE; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSPLANTATION; CLINICAL TRIALS; CORONARY VESSELS; FEMALE; GRAFT SURVIVAL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; KIDNEY; LEUKOCYTES, MONONUCLEAR; LIVER; LUNG; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; OXYQUINOLINE; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SPLEEN; SUS SCROFA; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 24644459322     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.526749     Document Type: Article

References (38)

1. World Health Organization. The World Health Report. Geneva: World Health Organization; 2003.
2. Isner JM. Myocardial gene therapy. Nature. 2002;415:234-239.
3. Rebulla P, Giordano R. Cell therapy: an evolutionary development of transfusion medicine. Int J Cardiol. 2004;95(suppl 1):S38-S42.
4. Hassink RJ, Goumans MJ, Mummery CL, Doevendans PA. Human stem cells shape the future of cardiac regeneration research. Int J Cardiol. 2004;95(suppl 1):S20-S22.
5. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002;136:54-71.
6. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, Imada T, Iwasaka T. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myoocardium. Arterioscler Thromb Vasc Biol. 2002;22:1804-1810.
7. Losordo DW, Vale PR, Isner JM. Gene therapy for myocardial angiogenesis. Am Heart J. 1999;138:S132-S141.
8. Britten MB, Abolmaali ND, Assmus B, Lehmann R, Honold J, Schmitt J, Vogl TJ, Martin H, Schachinger V, Dimmeler S, Zeiher AM. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003;108:2212-2218.
9. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
10. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929-933.
11. Menasché P, Hagège A, Scorsin M, Pouzet M, Desnos M, Duboc M, Schwartz K, Vilquin JT, Marolleau JP. Myoblast transplantation for heart failure. Lancet. 2001;357:279-280.
12. Chin RCJ, Zibaitis A, Kao RL. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg. 1995;:12-18.
13. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-148.
14. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92-95.
15. Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N; Angiogene GENe Therapy (AGENT-2) Study Group. A randomized, double blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003;42:1339-1347.
16. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER; VIVA Investigators. The VIVA trial: Vascular endothelial growth factor in ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359-1365.
17. Herreros J, Prosper F, Perez A, Gavira JJ, Garcia-Velloso MJ, Barba J, Sanchez PL, Canizo C, Rabago G, Marti-Climent JM, Hernandez M, Lopez-Holgado N, Gonzalez-Santos JM, Martin-Luengo C, Alegria E. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur Heart J. 2003;24:2012-2020.
18. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999;100:468-474.
19. Losordo DW, Vale PR, Symes JF. Angiogenesis gene therapy: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-2804.
20. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isnet JM. Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000;02:965-974.
21. Smits P, Van Geuns RJ, Poldermans D, Bountioukos M, Onderwater E, Lee CH, Maat A, Serruys P. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure. J Am Coll Cardiol. 2003;42:2063-2069.
22. Hou DM, Cates P, Bekkers S, Miller MA, Carl L, Rouch CL, March KL. Efficient myocardial delivery of microspheres and endothelial cells via selective retrograde coronary venous delivery. J Am Coll Cardiol. 2002;39:A76. Abstract.
23. Hou DM, McLaughlin F, Thiesse M, Rogers P, Johnson R, Wang J, Rothe E, Coleman ME, March KL. Widespread regional myocardial transfection by plasmid encoding Del-1 after retrograde coronary venous delivery. Cathet Cardiovasc Interv. 2003;58:207-211.
24. Boekstegers P, Von Degenfeld G, Giehrl W. Myocardial gene transfer by selective pressure regulated retroinfusion of coronary veins. Gene Ther. 2000;7:232-240.
25. Herity NA, Lo ST, Oei F. Selective regional myocardial infiltration by the percutaneous coronary venous route: a novel technique for local drug delivery. Cathet Cardiovasc Interv. 2000;51:358-363.
26. Thompson C, Nasser B, Makower J. Percutaneous transvenous cellular cardiomyoplasty: a novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol. 2000;39:75A. Abstract.
27. Hou DM, March KL. A novel percutaneous technique for accessing the normal pericardium: a single-center successful experience of 53 porcine procedures. J Invas Cardiol. 2003;15:13-17.
28. Waxman S, Pulerwitz TC, Rowe KA, Quist WC, Verrier RL. Preclinical safety testing of percutaneous transatrial access to the normal pericardial space for local cardiac drug delivery and diagnostic sampling. Cathet Cardiovasc Interv. 2000;49:472-477.
29. Laham RJ, Simons M, Hung D. Subxyphoid access of the normal pericardium: a novel drug delivery technique. Cathet Cardiovasc Interv. 1999;47:109-111.
30. Macris MP, Igo SR. Minimally invasive access of the normal pericardium: initial clinical experience with a novel device. Clin Cardiol. 1999;22(suppl I):I-36-I-39.
31. Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation. 2004;109:3154-3157.
32. Rabelink TJ, de Boer HC, de Koning EJ, van Zonneveld AJ. Endothelial progenitor cells: more than an inflammatory response. Arterioscler Thromb Vasc Biol. 2004;24:834-838.
33. Makkar RR, Lill M, Chen PS. Stem cell therapy for myocardial repair: is it arrhythmogenic?. J Am Coll Cardiol. 2003;42:2070-2072.
34. Simons M, Bonow RO, Chronos NA. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation. 2000;102:e73-e86.
35. Adegboyega PA, Adesokan A, Haque AK, Boor PJ. Sensitivity and specificity of triphenyl tetrazolium chloride in the gross diagnosis of acute myocardial infarcts. Arch Pathol Lab Med. 1997;121:1063-1068.
36. Berthold F. Isolation of human monocytes by Ficoll density gradient centrifugation. Blut. 1981;43:367-371.
37. Sharefkin JB, Lather C, Smith M, Rich NM. Endothelial cell labeling with indium-111-oxine as a marker of cell attachment to bioprosthetic surfaces. J Biomed Mater Res. 1983;17:345-357.
38. McAfee JG, Subramanian G, Gagne G. Technique of leukocyte harvesting and labeling: problems and perspectives. Semin Nucl Med. 1984;14:83-106.